重组人P53腺病毒联合放疗治疗鼻咽癌的临床研究

发布时间：2018-01-20 12:41

  本文关键词： P53基因 鼻咽癌 放射治疗　出处：《安徽医科大学》2010年硕士论文　论文类型：学位论文

【摘要】： 目的:评价重组人P53腺病毒注射液(rAd-p53)联合放疗治疗鼻咽癌的疗效及可能出现的毒副作用。 方法:选择安徽医科大学第一附属医院病理科诊断证实的III、IV期原发鼻咽癌16例,两组性别、年龄、病灶大小、照射野、放疗剂量均衡性检验均无统计学意义(P0.05)。鼻咽癌随机分为基因治疗联合放疗组(治疗组)8例和单纯放疗组(对照组)8例,治疗组:每周五予重组人P53腺病毒注射液1 ml鼻咽部瘤体注射,每周一开始行面颈联合野放疗,每日2 Gy,连续5 d,连续治疗6周。重组人P53腺病毒注射液由深圳赛百诺基因技术有限公司生产,规格:1×1012 VP/支。使用药物时从-20℃冰箱取出,室温静置融化后半小时内使用。采用鼻窦内窥镜引导下瘤内注射给药方式,肿瘤φ4 cm的,用生理盐水稀释到2 ml使用;肿瘤φ4 cm用生理盐水稀释到4 ml后使用。每次瘤体注射药物时均拍摄照片,以便自身前后对照。对照组:每周连续5 d行鼻咽癌面颈联合野常规放疗,每日2 Gy,连续治疗6周。治疗前3天、治疗后1周及治疗后1个月两组分别予血常规、血生化、尿常规和心电图检查;治疗前3天及治疗后1个月分别予鼻咽部CT检查。两组鼻咽部剂量均为70 Gy/35次,颈部淋巴结放疗剂量均为60Gy/30次。 结果: 1.两组均予鼻咽部CT扫描检查,对照组治疗后一月与治疗前相比,瘤体退缩不明显。 2.治疗组治疗后一个月与治疗前相比,瘤体退缩明显。 3.自身对照比较,治疗前后瘤体退缩明显,差异有统计学意义(P0.05)。 4.治疗组治疗前后血常规、尿常规、肝肾功能相关指标差异无统计学意义,心电图未见明显异常。 5.除了自限性低热外,未见其它不良反应。 6.基本状况各项评分中,除情感状况评分差异有统计学意义外,其余几项评分均无统计学意义。 结论: 1.重组人P53腺病毒注射液联合放疗治疗鼻咽癌具有较好疗效。 2.重组人P53腺病毒注射液联合放疗治疗鼻咽癌安全,不良反应患者可以耐受。
[Abstract]:Aim: to evaluate the efficacy and side effects of recombinant human adenovirus p53 (rAd-p53) combined with radiotherapy in the treatment of nasopharyngeal carcinoma (NPC). Methods: sixteen cases of primary stage IIIIV nasopharyngeal carcinoma confirmed by pathology in the first affiliated Hospital of Anhui Medical University were selected. The two groups were sex, age, lesion size and irradiation field. There was no statistical significance in dose balance test. Nasopharyngeal carcinoma was randomly divided into gene therapy combined with radiotherapy group (8 cases) and radiotherapy group (control group 8 cases). Treatment group: 1 ml of recombinant human p53 adenovirus injection was injected into nasopharynx tumor every Friday. The patients were treated with face neck combined with field radiotherapy at the beginning of one week, 2 Gy daily for 5 days. The recombinant human p53 adenovirus injection was produced by Shenzhen Sebenor Gene Technology Co., Ltd., with the specification of 1 脳 1012 VP1 / branch. The drug was removed from the refrigerator at -20 鈩，

本文编号：1448221